| Not Yet Recruiting | CUE-101with Pembrolizumab for LA-HPV+HNSCCs NCT07172256 | Yale University | Phase 2 |
| Recruiting | Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC NCT07155850 | BetaGlue Therapeutics SpA | N/A |
| Recruiting | BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or NCT07193511 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced NCT07028125 | Centre Francois Baclesse | Phase 4 |
| Not Yet Recruiting | Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer NCT07018063 | zhoujing | Phase 2 |
| Recruiting | Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer NCT06865339 | Montefiore Medical Center | Phase 2 |
| Not Yet Recruiting | A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1 NCT07046780 | PENG YUAN | — |
| Recruiting | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced NCT07038343 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer NCT06678659 | Recursion Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Recruiting | Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors NCT06416007 | University of Cincinnati | Phase 2 |
| Recruiting | PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC NCT06102057 | TheraOp | Phase 2 |
| Recruiting | Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy NCT06020430 | Hubei Cancer Hospital | N/A |
| Recruiting | Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer NCT06120387 | Xuesong Li | — |
| Recruiting | Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer NCT05679674 | Baptist Health South Florida | N/A |
| Recruiting | Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk NCT05877573 | Nanfang Hospital, Southern Medical University | N/A |
| Recruiting | Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced No NCT05766800 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Recruiting | SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rec NCT05576480 | Ruijin Hospital | Phase 2 |
| Recruiting | The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced NCT05802394 | Peking Union Medical College Hospital | N/A |
| Recruiting | TAD After Chemotherapy in Locally Advanced Breast Cancer NCT05763641 | Hospital Universitari de Bellvitge | — |
| Unknown | Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer NCT05868317 | Salah Azaïz Cancer Institute | Phase 2 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Completed | Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors NCT03644056 | ImmuneOncia Therapeutics Inc. | Phase 1 |
| Unknown | Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma NCT03024489 | Mahidol University | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Tr NCT03093922 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas NCT01318642 | NantBioScience, Inc. | Phase 2 |
| Completed | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) NCT01327612 | Amgen | Phase 2 |
| Completed | PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study NCT00911170 | Amgen | Phase 3 |
| Terminated | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors NCT00819169 | NantCell, Inc. | Phase 1 / Phase 2 |
| Completed | Cetuximab + Gemox in Biliary Tract Cancer NCT01216345 | Association of Research on the Biology of Liver Tumors | Phase 2 |
| Completed | A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients W NCT00378313 | NSABP Foundation Inc | Phase 2 |